Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ARTHEx 01

Next Previous
X
Search
Drug Profile

ARTHEx 01

Alternative Names: antagomiR-23b; AntimiR-23b; ARTHEx-01; ATX-01 - ARTHEx Biotech; ATX-02

Latest Information Update: 28 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ARTHEx Biotech
  • Developer ARTHEx Biotech; University of Valencia
  • Class Antirheumatics; Antisense RNA; MicroRNAs; Nucleic acids; Small molecules
  • Mechanism of Action Gene silencing; MicroRNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myotonic dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Myotonic dystrophy
  • Research Osteoarthritis

Most Recent Events

  • 28 Aug 2024 No recent reports of development identified for preclinical development in Myotonic dystrophy in Spain (IV, Infusion)
  • 24 May 2024 Phase-I/II clinical trials in Myotonic dystrophy in USA (IV) (NCT06300307)
  • 28 Feb 2024 ARTHEx Biotech plans a first-in human phase I/IIa ArthemiR™ clinical trial for Myotonic dystrophy in the USA in Q2 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top